- Home
- GB vs ADPT Comparison
GB vs ADPT Comparison
Compare GB & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GB
- ADPT
- Stock Information
- Founded
- GB 1980
- ADPT 2009
- Country
- GB Switzerland
- ADPT United States
- Employees
- GB N/A
- ADPT N/A
- Industry
- GB EDP Services
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GB Technology
- ADPT Health Care
- Exchange
- GB Nasdaq
- ADPT Nasdaq
- Market Cap
- GB 1.3B
- ADPT 1.2B
- IPO Year
- GB N/A
- ADPT 2019
- Fundamental
- Price
- GB $7.31
- ADPT $8.27
- Analyst Decision
- GB Buy
- ADPT Buy
- Analyst Count
- GB 1
- ADPT 5
- Target Price
- GB $6.00
- ADPT $9.10
- AVG Volume (30 Days)
- GB 1.2M
- ADPT 1.4M
- Earning Date
- GB 02-26-2025
- ADPT 02-11-2025
- Dividend Yield
- GB N/A
- ADPT N/A
- EPS Growth
- GB 422.66
- ADPT N/A
- EPS
- GB 0.21
- ADPT N/A
- Revenue
- GB $517,909,882.00
- ADPT $178,957,000.00
- Revenue This Year
- GB $21.30
- ADPT $20.07
- Revenue Next Year
- GB $11.47
- ADPT $25.27
- P/E Ratio
- GB $34.92
- ADPT N/A
- Revenue Growth
- GB 21.84
- ADPT 5.10
- 52 Week Low
- GB $4.26
- ADPT $2.28
- 52 Week High
- GB $8.00
- ADPT $8.95
- Technical
- Relative Strength Index (RSI)
- GB 58.39
- ADPT 58.94
- Support Level
- GB $7.29
- ADPT $8.09
- Resistance Level
- GB $7.36
- ADPT $8.69
- Average True Range (ATR)
- GB 0.34
- ADPT 0.64
- MACD
- GB 0.06
- ADPT -0.00
- Stochastic Oscillator
- GB 95.97
- ADPT 65.66
About GB Global Blue Group Holding AG
Global Blue Group Holding AG offers a seamless shopping and payment journey for tourists and also provides a wide range of Added-Value Payment Solutions for all the stakeholders involved, including retailers and international shoppers. The company connect thousands of retailers, acquirers, and hotels with nearly 80 million consumers across more than 50 countries, in three industries: Tax Free Shopping, Payments and Post-Purchase solutions.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).